Use of hormone replacement therapy in 1976–89 by 45–64 year old Finnish women

Päivi Topo, Timo Klaukka, Elina Hemminki, Antti Uutela

Abstract

Study objective—The aim was to describe changes in the use of hormone replacement therapy (HRT) in Finland during the period 1976–1989.


Participants—Participants were national samples of non-institutionalized Finnish women 45–64 years of age. Participation rates ranged from 85% to 96%.

Measurements and main results—Current reported hormone use in the surveys of 1976, 1978–1980, and 1987 was assessed, together with reported hormone use in the last month in the 1989 survey. During the study period the proportion of HRT users increased fivefold. In 1989, 20% of women reported current use of HRT, and the highest rate of use was found among 50–54 year old women in the Helsinki area. In 1976, users were mainly women around the age of menopause, those living in the capital area, and those having a rather high level of education. By 1989 use had spread to postmenopausal women, those in rural areas, and those with less education.

Conclusions—Use of HRT has increased in Finland. It is difficult to evaluate whether the level of current use is too high, optimal, or too low, because recommendations are contradictory and the long term effects of HRT are unknown.

Hormone replacement therapy (HRT) during the menopause and in the postmenopausal period has been available for more than 40 years. At first only oestrogens were used in many countries. Later, when the relation between oestrogen therapy and endometrial cancer was discovered oestrogen-progestin combinations became more common. Researchers have been interested in HRT because of its popularity, its uncertain indications, and the lack of information about side effects from long term use. The identification of osteoporosis as a major public health problem has been a further stimulus for research.

Despite the popularity of HRT there is little information about HRT users. All previous data on the changes in the use of HRT are based on numbers of prescriptions or sales. In this article we report how HRT usage has changed in Finland in different age and socioeconomic groups as well as regionally. Our data derive from three nationwide interview studies and a mail questionnaire survey. In addition we have made use of sales figures for these medicines.

Methods

Strictly speaking, the menopause is defined as the final menstrual bleeding. In this study menopause means the symptomatic period around the last menstrual bleeding. Because our data do not permit us to define the exact time of the menopause of the women studied, we shall call all women of at least 55 years of age postmenopausal.


SURVEY 1

The material of the 1976 study was derived from a nationwide health interview survey. The data were collected through household interviews carried out by public health nurses from local health centres. The sample (16 413 adults and 4605 children) represented the total non-institutionalized population of the country; the participation rate was 91%.

SURVEY 2

The same methodology as above was used in the 1987 study. The sample size was 13 138 adults and 3131 children, and the participation rate was 85%.

SURVEY 3

The Mini-Finland Health Survey in 1978–1980 in 40 areas contained an interview, which was methodologically identical with those in the previous two health surveys. The study population consisted of 7612 people, who were at least 30 years old, and the participation rate was 96%.

SURVEY 4

In 1989 a random sample (n = 2000) of all Finnish women 45–64 years of age was drawn from the Finnish Population Register, and a questionnaire on the menopause and the use of health services and drugs was mailed to them. The answers were anonymous, and those who responded were identified by a name tag which they returned in a separate envelope. The response rate after two reminders was 86%.

The question concerning use of medicines in the studies of 1976, 1978–1980, and 1987 was the following: ‘‘What prescription drugs do you use at the moment?’’ The names of the drugs were
copied from the prescription forms or containers for all drugs they were currently using. In the 1989 study, the use of HRT was determined by the question: “Have you used hormones (oestrogens or oestrogen-progestin combinations) during the last month (30 days)? State the name of the drug.”

The medicines classified in the Finnish drug compendium, Pharmaca Fennica, for menopausal and postmenopausal hormonal treatment, and containing either oestrogens alone, oestrogens combined to progestins, or oestrogens combined to other drugs, were included. Progestin taken alone was not included. Pharmaca Fennica classifies drugs in a way similar to the ACT classification used by the Nordic Council on Medicines.

In each survey the level of general education included three alternatives: primary school (7-8 years), junior secondary school (9-10 years), and senior secondary school (12-13 years). In 1976 and 1987 respondents’ place of residence was classified as the Helsinki metropolitan area (including Helsinki and three neighbouring towns), other towns, and rural areas. In 1989 the name of the municipality was not asked, and the Helsinki metropolitan area was defined as all the towns located in the county, which made the category much larger than in the other studies.

The sales figures for hormones mainly used for HRT—GO3F, GO3C and GO3E in the official Nordic ATC drug classification—were obtained for the years 1981-1986 from a previously published article and in 1987-1989 from Finnish Statistics on Medicines. The sales figures were given as defined daily doses (DDD).

Statistical significance of differences in distributions were tested by $\chi^2$ test. Differences were tested between the study years and between the various subgroups within a year separately.

**Results**

During the first 11 years studied, HRT usage among 45-64 year old women increased threefold (from 4% to 12%), (table 1). In 1989 the number of current HRT users increased further nearly twofold. While this increase occurred in every age group, most interesting is the rapid increase in HRT use among 55-64 year old postmenopausal women. All the differences between the years were statistically significant (p < 0.001). For all periods, use of HRT was most common in the age group 50-54 years. The variation in the treatment length was notable: 32% of the users had used it, this far, for at most a year, 43% between 13 months and 5 years, and 25% more than 5 years. As expected, short treatments were more common among young women and long treatments among older women: 37% of the 60 years or older users has used HRT more than 5 years. Furthermore sales figures show an increase in the use of oestrogen, oestrogen combined with progestin, and oestrogen combined with other drugs in the period 1981-1989. The increase has been more rapid after 1986 (fig 1).

![Figure 1 Sales of hormones used in menopause and postmenopause in Finland 1981-1989, in defined daily dose (DDD).](image-url)

**Table I. Use of hormone replacement therapy by age and area of residence, 1976, 1987, and 1989**

<table>
<thead>
<tr>
<th>Year</th>
<th>Age (years)</th>
<th>Area of residence</th>
<th>1976 $n$ (n)</th>
<th>1987 $n$ (n)</th>
<th>1989 $n$ (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1976</td>
<td>45-49</td>
<td>Helsinki</td>
<td>7 (112)</td>
<td>9 (92)</td>
<td>12 (64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other towns</td>
<td>3 (324)</td>
<td>14 (305)</td>
<td>11 (140)</td>
</tr>
<tr>
<td></td>
<td>50-54</td>
<td>Rural areas</td>
<td>1 (337)</td>
<td>5 (226)</td>
<td>8 (115)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Helsinki</td>
<td>12 (81)</td>
<td>29 (73)</td>
<td>40 (77)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other towns</td>
<td>10 (307)</td>
<td>26 (215)</td>
<td>26 (180)</td>
</tr>
<tr>
<td></td>
<td>55-59</td>
<td>Rural areas</td>
<td>5 (331)</td>
<td>14 (182)</td>
<td>25 (173)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Helsinki</td>
<td>2 (77)</td>
<td>22 (64)</td>
<td>37 (71)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other towns</td>
<td>2 (231)</td>
<td>9 (211)</td>
<td>21 (164)</td>
</tr>
<tr>
<td></td>
<td>60-64</td>
<td>Rural areas</td>
<td>1 (290)</td>
<td>8 (191)</td>
<td>20 (154)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Helsinki</td>
<td>3 (64)</td>
<td>17 (47)</td>
<td>29 (65)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other towns</td>
<td>0 (186)</td>
<td>4 (206)</td>
<td>14 (215)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>Rural areas</td>
<td>0 (247)</td>
<td>3 (196)</td>
<td>9 (205)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Helsinki</td>
<td>6 (396)</td>
<td>17 (322)</td>
<td>30 (282)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other towns</td>
<td>4 (1225)</td>
<td>12 (1104)</td>
<td>18 (722)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rural areas</td>
<td>2 (1389)</td>
<td>7 (958)</td>
<td>15 (674)</td>
</tr>
</tbody>
</table>

(Numbers in parentheses give denominators)

HRT use was more common in towns than in rural areas during the whole study period (table II) and most common in the capital area. The subgroup with the highest level of use was 50-54 year old women living in the Helsinki area. Increase in use from 1976 to 1987 was, however, greatest in the countryside (a 7.5-fold increase) and the urban-rural difference became smaller in 1989. All these differences between the areas of residence were statistically significant (p at least <0.01).

Use of HRT was infrequent in the oldest age group (60-64 years) in 1986, with none of the rural women 60 to 64 years old using HRT. With time, HRT use also appeared in the oldest age group (table II).
Use of HRT by 45-64 year old women

The more education women had the more likely they were to use HRT (fig 2). (The differences between the educational groups were statistically significant, with p at least <0.01.) The educational level of the general population had risen between 1976 and 1989, so that younger age groups were better educated in 1989 than in 1976. For this reason we combined age with education in using data of HRT. A relationship between education and HRT use was systematic only among women of 55 years or over.

Discussion

Both population surveys and sales statistics produced similar information about a general increase in HRT usage in Finland. The varying data collection method in the 1989 survey as compared to the previous surveys may have influenced the exact estimate of the level of use, but is unlikely to bias the trend. This development in Finland has differed from that in the United States, where use of HRT declined in the mid 1970s and increased again in the 1980s.3 4 17 18 Comparing sales figures, HRT has been used less in Finland than in Denmark and Sweden but more than in Norway.19

Studies from other countries have also shown the highest level of use to be among 50-54 year old women.8 16 At 50-54 years, menopausal symptoms are most prominent. Because in our study period, use also became more common for those aged 55 years and over, the indications for HRT are probably becoming more orientated to the prevention of osteoporosis and other health problems of old age.

The fact that better educated women make more use of HRT has also been found in other studies,8 though conflicting results have been published.5 An important finding of the Finnish studies is that the first people to adopt HRT were highly educated women, its use then spreading to other educational groups. The same rule seems to be applicable to the place of residence, with use spreading from the capital metropolitan area to the rural areas. This is similar to certain other health related movements—for example the now widespread use of vitamin supplements in Finland followed the same pattern.23

Reasons for this increased popularity of HRT may be that there are now more gynaecological services available, doctors’ attitudes towards HRT may have changed, and women are better informed about HRT than before. A great majority of Finnish working age women are in the labour force, which may increase their willingness to use HRT to minimise menopausal discomforts.

One important question concerns the optimal level of HRT use. In regard to the prevention of osteoporosis, a Finnish group of experts established by the National Board of Health, concluded that all postmenopausal women without contraindications should be prescribed HRT to prevent osteoporosis.24 By this criterion, HRT use in Finland is still too low. The Swedish National Board of Health and Welfare25 took a more cautious stand, recommending HRT for prevention of osteoporosis only for women with prolonged periods of amenorrhoea or early menopause. The number of such women is probably smaller than the current numbers of users of HRT in Finland. A consensus development conference, sponsored by the European Foundation for Osteoporosis and Bone Disease, recommended HRT for osteoporosis prophylaxis only for women identified as being at risk.26 Because it is expensive and technically difficult to establish that a woman is at risk of contracting postmenopausal osteoporosis, this approach may not be feasible in practice.

An additional fact in this controversial field is that the long term benefits and dangers of HRT are not known. For example there are contradictory results on the association between HRT and breast cancer22 27 28 and cardiovascular diseases.27 29-32 Therefore a cautious attitude towards a widespread use of HRT should probably be adopted.

Use of hormone replacement therapy in 1976-89 by 45-64 year old Finnish women.

P Topo, T Klaukka, E Hemminki and A Uutela

*J Epidemiol Community Health* 1991 45: 277-280
doi: 10.1136/jech.45.4.277

Updated information and services can be found at:
http://jech.bmj.com/content/45/4/277

*Email alerting service*

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/